Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into…
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively…
Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, June 22, 2023…
Media ReleaseCOPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody,…
Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza®…
Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled…
First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroupsNoninvasive imaging and biomarker data…
J-A. Sahel (left)_B.Roska (right) J-A. Sahel (left)_B.Roska (right)Basel, Switzerland, June 22, 2023 --In recognition of their pioneering work on restoring…
Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at…
Company reaches another clinical trial milestone for treatment of Tourette’s with its novel SCI-110 therapy in the United States TEL…